



## Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

June 2, 2026

WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026 at 8:40 a.m. ET.

A live webcast of the fireside chat will be available on the [Events and Presentations](#) section of Palvella's website at [www.palvellatx.com](http://www.palvellatx.com). An archived replay of the webcast will be available for approximately 90 days following the fireside chat.

### About Palvella Therapeutics

Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella's second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit [www.palvellatx.com](http://www.palvellatx.com) or follow Palvella on [LinkedIn](#) or [X](#) (formerly known as Twitter).

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.

### Contact Information

#### Investors

Wesley H. Kaupinen  
Founder and CEO, Palvella Therapeutics  
[wes.kaupinen@palvellatx.com](mailto:wes.kaupinen@palvellatx.com)

#### Media

Marcy Nanus  
Managing Partner, Trilon Advisors LLC  
[mnanus@trilonadvisors.com](mailto:mnanus@trilonadvisors.com)